Friday, June 28, 2024
Elucid, a pioneering medical technology company focused on cardiovascular disease treatment, has relocated its headquarters to 399 Boylston Street in Boston’s Back Bay neighborhood.
This move coincides with Elucid’s growth and its preparations for the commercial launch of its flagship plaque analysis software.
Following an $80 million Series C funding round led by Elevage Medical Technologies in late 2023, the company is expanding its workforce and operational capacity.
The new headquarters spans more than 16,000 square feet and is strategically located near Boston Public Garden and various public transit stops.
Designed to encourage collaboration and prioritize employee well-being, the office features abundant natural light, collaborative workspaces, and amenities such as a gym, locker room, and bike storage.
The new space will enhance team cohesion and support the company’s three-year strategic plan.
Elucid’s flagship software, validated by histology and FDA-cleared, enables non-invasive quantification and characterization of non-calcified plaque components like lipid-rich necrotic core (LRNC).
This technology offers critical insights into high-risk plaques, which significantly contribute to heart attacks and strokes worldwide.
Additionally, Elucid is advancing its PlaqueIQ technology to potentially measure fractional flow reserve (FFRCT), enhancing its ability to assess coronary blockages and ischemic extent without invasive procedures.
Source: businesswire.com
